Published in Drug Saf on January 01, 2001
Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano (2010) 1.82
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
"Clickable" polymer-caged nanobins as a modular drug delivery platform. J Am Chem Soc (2009) 1.18
Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine (2006) 1.13
Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods (2008) 1.09
Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia (2004) 1.08
Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine (2008) 1.06
Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest (2015) 1.03
Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc (2010) 0.94
Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia. J Control Release (2013) 0.93
A machine learning approach to identify clinical trials involving nanodrugs and nanodevices from ClinicalTrials.gov. PLoS One (2014) 0.89
Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases. Biogerontology (2014) 0.87
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res (2012) 0.86
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv (2013) 0.83
A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. J Pharm Biomed Anal (2015) 0.80
High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy (2010) 0.80
Triggered release of pharmacophores from [Ni(HAsO₃)]-loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study. ACS Nano (2011) 0.78
Hydroxycamptothecin liposomes inhibit collagen secretion and induce fibroblast apoptosis in a postlaminectomy rabbit model. Eur J Orthop Surg Traumatol (2012) 0.78
Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects. Oncotarget (2015) 0.77
Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study-A Single-Center, Blinded, Randomized Controlled Trial. Clin Cardiol (2016) 0.76
Intracellular trafficking of a pH-responsive drug metal complex. J Control Release (2016) 0.75
Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study. Oncol Lett (2010) 0.75
Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. Ecancermedicalscience (2008) 0.75
Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus (2016) 0.75
Low-temperature 1H-NMR spectroscopic study of doxorubicin influence on the hydrated properties of nanosilica modified by DNA. J Mater Sci Mater Med (2011) 0.75
Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: High loading capacity, increased stability, and improved anticancer efficacy. Biomaterials (2017) 0.75
Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta (1986) 7.07
Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta (1985) 4.47
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci (2000) 2.81
Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta (1985) 2.05
Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat (2008) 1.64
Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs (1994) 1.59
Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep (2002) 1.53
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta (1986) 1.52
Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta (1985) 1.49
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res (1989) 1.47
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids (1990) 1.31
Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry (1982) 1.25
Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry (2000) 1.22
Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta (1990) 1.21
Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids (1986) 1.18
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta (1985) 1.18
Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci (2000) 1.18
Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther (2001) 1.17
Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer (1995) 1.16
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta (1998) 1.11
Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol (1999) 1.10
Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol (1993) 1.07
Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res (1994) 1.07
Cromolyn sodium in the treatment of grass pollen asthma. Ann Allergy (1972) 1.06
Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer (1995) 1.05
Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem (1990) 1.05
Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res (1990) 1.04
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta (1997) 1.04
Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res (2000) 1.02
Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods (1990) 1.02
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene (2010) 1.01
Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther (1997) 1.01
In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des (2000) 1.00
Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett (1990) 0.99
Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry (1995) 0.98
Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta (2001) 0.96
Prothrombin association with phospholipid monolayers. Biochemistry (1983) 0.96
Phase I study of liposomal vincristine. J Clin Oncol (1999) 0.95
Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res (2000) 0.95
Self-assembling DNA-lipid particles for gene transfer. Pharm Res (1997) 0.95
Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J (1998) 0.95
Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol (1998) 0.93
The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther (1997) 0.93
Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res (2000) 0.92
A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta (1987) 0.92
Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta (1990) 0.92
Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anticancer Agents (2001) 0.91
Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry (1984) 0.91
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol (1989) 0.89
Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat (2000) 0.89
Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol (2001) 0.89
Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol (1994) 0.88
Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther (2000) 0.88
Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets (2006) 0.88
Kinetic and hydrodynamic analysis of blood clotting factor V-membrane binding. Biochemistry (1982) 0.87
Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta (2001) 0.87
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res (2012) 0.87
Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem (1983) 0.87
Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol (1983) 0.87
Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol (1998) 0.86
Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine (2001) 0.86
Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res (1997) 0.86
The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res (2000) 0.85
Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids (1988) 0.85
Cationic lipid binding to DNA: characterization of complex formation. Biochemistry (1996) 0.85
pH gradients and membrane transport in liposomal systems. Trends Biotechnol (1991) 0.84
Calcium and prothrombin-induced lateral phase separation in membranes. Biochemistry (1981) 0.84
Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci (1996) 0.84
Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer (2000) 0.84
The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost (1990) 0.84
Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta (2001) 0.84
Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res (1999) 0.83
Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta (1993) 0.83
Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem (1995) 0.82
Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J (1989) 0.82
The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta (1993) 0.82
Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal (1997) 0.82
Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo (1993) 0.82
Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol (1990) 0.82